Combining sCD163 with CA 19-9 Increases the Predictiveness of Pancreatic Ductal Adenocarcinoma

SIMPLE SUMMARY: During the last decades, the CA 19-9 blood test has been the only widely used biomarker in patients with pancreatic ductal adenocarcinoma (PDAC). Given the poor prognosis and staggering mortality rates of this type of cancer, partly due to late diagnosis, new and easily available bio...

Descripción completa

Detalles Bibliográficos
Autores principales: Stuhr, Liva K., Madsen, Kasper, Johansen, Astrid Z., Chen, Inna M., Hansen, Carsten P., Jensen, Lars H., Hansen, Torben F., Kløve-Mogensen, Kirstine, Nielsen, Kaspar R., Johansen, Julia S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913074/
https://www.ncbi.nlm.nih.gov/pubmed/36765852
http://dx.doi.org/10.3390/cancers15030897

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913074/
https://www.ncbi.nlm.nih.gov/pubmed/36765852
http://dx.doi.org/10.3390/cancers15030897

Ejemplares similares